Acumen Pharmaceuticals (ABOS) Research & Development (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Research & Development of $16.5 million for Q1 2026, down 19.69% sequentially from $20.5 million in Q4 2025, and down 34.76% YoY from $25.3 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Research & Development (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Research & Development for 7 years, with the latest figure at $16.5 million in Q1 2026.
- Quarterly Research & Development fell 34.76% year-over-year to $16.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.1 million (down 9.86% YoY) and the FY2025 annual result came in at $104.9 million, up 11.82% from the prior year.
- Research & Development declined to $16.5 million in Q1 2026 per ABOS's latest filing, from $20.5 million in the prior quarter.
- Over five years, Research & Development peaked at $37.1 million in Q2 2025 and troughed at $6.0 million in Q1 2022.
- A 5-year average of $17.0 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 361.61% in 2022, then sank 40.62% in 2025.
- Over 5 years, Research & Development stood at $10.7 million in 2022, then increased by 23.7% to $13.3 million in 2023, then jumped by 160.05% to $34.6 million in 2024, then tumbled by 40.62% to $20.5 million in 2025, then slipped by 19.69% to $16.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $16.5 million, $20.5 million, and $22.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Acumen Pharmaceuticals | 229.03 Mn | 229.03 Mn | - | 27.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.81 Mn |
| Mar 31, 2026 | 16.48 Mn |
| Dec 31, 2025 | 20.53 Mn |
| Sep 30, 2025 | 21.97 Mn |
| Jun 30, 2025 | 37.13 Mn |
| Mar 31, 2025 | 25.27 Mn |
| Dec 31, 2024 | 34.57 Mn |
| Sep 30, 2024 | 27.25 Mn |
| Jun 30, 2024 | 19.53 Mn |
| Mar 31, 2024 | 12.45 Mn |
| Dec 31, 2023 | 13.29 Mn |
| Sep 30, 2023 | 11.18 Mn |
| Jun 30, 2023 | 9.13 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | 10.75 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 7.32 Mn |
| Mar 31, 2022 | 5.99 Mn |
| Dec 31, 2021 | 5.67 Mn |
| Sep 30, 2021 | 1.80 Mn |